

and the size or number of LN metastasis is not yet reflected in both the staging system and treatment modality. The therapeutic effect of surgical resection of bulky lymph node before standard treatment has been reported in several retrospective studies. However, there are lack of well-planned randomized clinical study. Therefore, the aim of the Korean Gynecologic Oncology Group (KGOG) 1047/DEBULK trial is to investigate whether the debulking surgery of bulky or multiple LNs prior to concurrent chemoradiation therapy (CCRT) improves the survival rate in cervical cancer IIICr as diagnosed by imaging.

Methods The KGOG 1047/DEBULK trial is a phase III, multi-center, randomized clinical trial of patients with bulky or multiple lymph node metastasis in cervical cancer IIICr. This study included patients with a short-axis of a pelvic or para-aortic LN ≥ 2 cm or more than 3 LNs with a short axis ≥ 1 cm and for whom CCRT is planned. The treatment arms will randomly be allocated to undergo either CCRT (control arm) or surgical debulking of bulky or multiple LNs prior to CCRT (experimental arm). Total 234 patients will be included (117 patients per each group) within 4 years. The primary endpoint is 3-year progression free survival. The secondary endpoints are the treatment-related complications and the radiologic accuracy.

Current Trial Status Twenty-two Korean institutions have confirmed their participation, and are preparing for international joint research with India, Vietnam, and Malaysia. There are currently 15 patients enrolled.

AS04. Endometrial/Uterine corpus cancers

TP007/#1383

A PHASE II STUDY OF INDUCTION PD-1 BLOCKADE (NIVOLUMAB) IN PATIENTS WITH SURGICALLY COMPLETELY RESECTABLE MISMATCH REPAIR DEFICIENT ENDOMETRIAL CANCER (NIVEC)

¹Amal Alsomairi*, ¹Jung-Yun Lee, ¹Yong Jae Lee, ²Hyun-Woong Cho, ³Jeong-Yeol Park, ⁴Yoo Young Lee, ⁵Sung Jong Lee, ⁶Myong Cheol Lim. ¹Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; ²Korea University Guro Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of; ³Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; ⁴Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of; ⁵Seoul St. Mary's hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of; ⁶Center for Gynecologic Cancer, National Cancer Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of

10.1136/ijgc-2023-IGCS.469

Introduction Mismatch repair deficient endometrial cancer (MMRd-EC) is a subtype of endometrial carcinoma which exhibits aggressive characteristics and poor prognosis. MMRd tumors are known to be highly immunogenic and of great interest for immune checkpoint inhibitor. There is lack of data regarding the efficacy of nivolumab as induction monotherapy in completely resectable MMRd-ECs. In this regard, we suggest a window of opportunity study of induction PD-1 blockade (nivolumab) in patients with surgically resectable MMRd-EC.

Methods This multi-center, non-randomized, open-label Phase II study plans to enroll 30 patients with surgically resectable MMRd-EC. Additional inclusion criteria include clinical stage

I-IIIC2, tumor specimen that demonstrates MMRd by immunohistochemistry or microsatellite instability as demonstrated by NGS or PCR. Exclusion criteria include multiple primary cancers, residual adverse effects of prior therapy or history of severe hypersensitivity to any antibody products. Patients will receive nivolumab at a dose of 480 mg IV, every 4 weeks as induction therapy for six cycles. Subsequently, patients will undergo surgery and/or receive adjuvant treatment following standard institutional guidelines. The primary endpoint is complete response rate of PD-1 blockade and surgery. Secondary endpoints include objective response rate, progression-free survival, overall survival, and adverse events. Correlative studies include genomic characterization of tumors, assessment of immune infiltration of tumor microenvironment, and serial circulating cell-free DNA and immune biomarkers.

Current Trial Status Open enrollment period: Dec/2022, to Dec/2024. The Target number: 30 patients. The study intends to provide valuable insights into the efficacy and safety of nivolumab as induction therapy for surgically resectable MMRd-EC.

TP008/#1500

TRIAL IN PROGRESS: PHASE 2/3 STUDY OF NAVTEMADLIN AS MAINTENANCE THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER WHO RESPONDED TO CHEMOTHERAPY (ENGOT-EN21; GOG-3089)

¹Nicole Concin*, ²Ugo De Giorgi, ^{3,4}Toon Van Gorp, ⁵Jérôme Alexandre, ^{6,7}Kristina Lindemann, ¹Christian Marth, ¹Regina Berger, ⁸David Cibula, ⁹Maria Quindos, ¹⁰Alessandra Bologna, ¹¹Jacob Korach, ¹²Christos Papadimitriou, ¹³Shibani Nicum, ¹⁴Dearbhaile Collins, ¹⁵Reg Myers, ¹⁵Wayne Rothbaum, ¹⁶Thomas Herzog, ¹⁷Bradley Monk, ¹⁸Noelle Gillette Cloven. ¹Medical University of Innsbruck, Univ-Clinic for Gynecology and Obstetrics, Innsbruck, Austria and AGO (Arbeitsgemeinschaft für gynäkologische Onkologie), Gynaecology and Obstetrics, Innsbruck, Austria; ²IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori' and Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Group, Department of Medical Oncology, Meldola, Italy; ³University Hospital Leuven, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Leuven, Belgium; ⁴Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, Leuven, Belgium; ⁵Université de Paris Cité, Hôpital Cochin, Medical Oncology, Paris, France; ⁶Oslo University Hospital, The Norwegian Radium Hospital, Department of Gynaecologic Cancer, Oslo, Norway; ⁷Institute of Clinical Medicine, University of Oslo and the Nordic Society of Gynaecological Oncology (NSGO) Group, Department of Gynaecologic Cancer, Oslo, Norway; ⁸General University Hospital in Prague, First Faculty of Medicine, Charles University, Department of Obstetrics and Gynaecology, Prague, Czech Republic; ⁹Complejo Hospitalario Universitario de A Coruña, Spanish Gynaecological Cancer Research Group (GEICO), Biomedical Research Institute (INIBIC), Medical Oncology Department, A Coruña, Spain; ¹⁰Azienda Unità Sanitaria Locale di Reggio Emilia-IRCCS, Department of Oncology, Reggio Emilia, Italy; ¹¹Sheba Medical Center, Gynecology Oncology, Ramat Gan, Tel Aviv, Israel; ¹²Aretaieion University Hospital, National and Kapodistrian University of Athens, Oncology Unit, Second Department of Surgery, Athens, Greece; ¹³University College London, Research Department of Oncology, London, UK; ¹⁴Cork University Hospital, Department of Medical Oncology, Cork, Ireland; ¹⁵Kartos Therapeutics Inc., Clinical Sciences Department, Redwood City, USA; ¹⁶University of Cincinnati Cancer Center, Obstetrics and Gynecology, Cincinnati, USA; ¹⁷HonorHealth Research Institute, University of Arizona, Creighton University School of Medicine, Obstetrics and Gynecology, Phoenix, USA; ¹⁸Texas Oncology-Fort Worth Cancer Center, Obstetrics and Gynecology, Fort Worth, USA

10.1136/ijgc-2023-IGCS.470

Introduction Advanced/recurrent endometrial cancer (EC) has poor prognosis with 5-year survival rate of ~17% (Colombo 2016; Siegel 2022). Maintenance treatment may extend the response to initial chemo/chemoimmunotherapy. Mouse